武田制药反垄断败诉面临最高约25亿美元天价赔偿,武田:将积极寻求审判后动议和上诉

蓝鲸财经
May 25

图片来源:武田制药全球官网  蓝鲸新闻5月25日讯 根据武田制药全球官网5月19日的新闻稿,美国马萨诸塞州地方法院陪审团于 2026 年 5 月 18 日(美国东部时间)就Amitiza(鲁比前列酮)反垄断诉讼作出了判决,裁定武田支付8.85亿美元单倍赔偿金,其中,批发商集体获赔4.749亿美元,个体零售商合计获赔3.468亿美元。根据美国反垄断法,针对批发商和零售商的赔偿部分将在法院判决生效后...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10